| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6346532 | APGDI | Amide derivatives or salts thereof |
Mar, 2022
(2 years ago) | |
| US7342117 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6346532 (Pediatric) | APGDI | Amide derivatives or salts thereof |
Sep, 2022
(1 year, 6 months ago) | |
| US7982049 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(5 months ago) | |
|
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(15 days from now) | |
|
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(15 days from now) | |
| US10058536 | APGDI | Pharmaceutical composition containing mirabegron |
Mar, 2036
(11 years from now) | |
|
US10058536 (Pediatric) | APGDI | Pharmaceutical composition containing mirabegron |
Oct, 2036
(12 years from now) | |
Myrbetriq Granules is owned by Apgdi.
Myrbetriq Granules contains Mirabegron.
Myrbetriq Granules has a total of 8 drug patents out of which 4 drug patents have expired.
Expired drug patents of Myrbetriq Granules are:
- US6346532*PED
- US7982049
- US6346532
- US7342117
Myrbetriq Granules was authorised for market use on 25 March, 2021.
Myrbetriq Granules is available in for suspension, extended release;oral dosage forms.
Myrbetriq Granules can be used as treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron.
The generics of Myrbetriq Granules are possible to be released after 01 October, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 25 March, 2021
Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
MYRBETRIQ GRANULES family patents
